1h Free Analyst Time
The stem cell umbilical cord blood (UCB) market is poised to grow by $1.47 bn during 2022-2026, accelerating at a CAGR of 16.87% during the forecast period. The report on the stem cell umbilical cord blood (UCB) market provides a holistic analysis of market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of several chronic disorders, increased federal investment in stem cell therapy, and the advent of cord blood banking.
The stem cell umbilical cord blood (UCB) market analysis includes the end-user segment and geographic landscape.
The stem cell umbilical cord blood (UCB) market is segmented as below:
By End-user
- Pharmaceutical
- Research institutes
- Hospitals
- Biobanks
By Geographical Landscape
- North America
- Asia
- Europe
- Rest of World (ROW)
The report on the stem cell umbilical cord blood (UCB) market covers the following areas:
- Stem cell umbilical cord blood (UCB) market sizing
- Stem cell umbilical cord blood (UCB) market forecast
- Stem cell umbilical cord blood (UCB) market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by End-user
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global stem cell umbilical cord blood (UCB) market: Americord Registry LLC, Athersys Inc., CBR Systems Inc., Cells4Life Group LLP, Celularity Inc., Cordlife Group Ltd., Cryo Cell International Inc., Cryo Stemcell, Cryoviva Biotech Pvt. Ltd., FamiCord Group, FUTURE CELL JAPAN, Global Cord Blood Corp., LifeCell International Pvt. Ltd., MEDIPOST Co. Ltd., Next Biosciences Pty Ltd., Regrow Biosciences Pvt Ltd., Smart Cells International Ltd., Smith and Nephew plc, ViaCord LLC, and Vita 34 International AG.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is increasing investments in the field of regenerative medicines.`
According to the report, one of the major drivers for this market is the rising prevalence of several chronic disorders.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Americord Registry LLC
- Athersys Inc.
- CBR Systems Inc.
- Cells4Life Group LLP
- Celularity Inc.
- Cordlife Group Ltd.
- Cryo Cell International Inc.
- Cryo Stemcell
- Cryoviva Biotech Pvt. Ltd.
- FamiCord Group
- FUTURE CELL JAPAN
- Global Cord Blood Corp.
- LifeCell International Pvt. Ltd.
- MEDIPOST Co. Ltd.
- Next Biosciences Pty Ltd.
- Regrow Biosciences Pvt Ltd.
- Smart Cells International Ltd.
- Smith and Nephew plc
- ViaCord LLC
- Vita 34 International AG
